How Semaglutide Works for Weight Loss: The Full Picture

Semaglutide is the most studied of the modern weight-loss medications, and also the most misunderstood. It is routinely described as an appetite suppressant, which is true but incomplete, and occasionally as a metabolism booster, which is false. What semaglutide actually does is more specific and more interesting: it is an engineered, long-lasting copy of a gut hormone the body already makes, and it produces weight loss by working on the appetite system from several directions at once. This article assembles the full picture — the receptor it targets, the three channels through which it changes how much you eat, the trial evidence for how much weight that produces, and the uncomfortable fact of what happens when the medication is stopped.

The starting point is that semaglutide does not introduce a foreign mechanism into the body. It amplifies one that is already running. To see how, it helps to begin with the hormone it is built from. For a plain-language primer on that hormone, see what GLP-1 is; this piece sits within the broader GLP-1 science guide and the wider GLP-1 science cluster.

What Semaglutide Is: A Durable Copy of GLP-1

GLP-1 — glucagon-like peptide-1 — is a hormone released by cells in the gut wall after a meal. Daniel Drucker's 2018 synthesis in Cell Metabolism sets out its core jobs: it prompts the pancreas to release insulin when blood sugar is high, it suppresses the sugar-raising hormone glucagon, it slows the rate at which the stomach empties, and it acts on the brain to promote satiety. It is, in effect, the body's post-meal coordinator, telling the pancreas, the stomach, and the brain at once that food has arrived.

The problem that kept GLP-1 from becoming a medicine for decades is that the natural hormone disappears almost instantly. An enzyme called DPP-4 degrades it within about two minutes of release. A signal that vanishes that fast is useless as a drug — inject it and you get a flicker of effect and nothing more.

Semaglutide is the engineering answer to that problem. It is a modified version of GLP-1 with two key changes: targeted substitutions in its amino-acid chain that block DPP-4 from cleaving it, and an attached fatty-acid chain that lets it bind to albumin, a carrier protein in the blood, so it circulates for days instead of minutes. The result is a molecule that activates the same GLP-1 receptor as the natural hormone but lasts roughly a week per dose — which is why it is injected once weekly. It is the same message the gut already sends after a meal, simply made to persist. The same molecule is sold as Ozempic for diabetes and Wegovy for weight management at higher doses; the relationship between those two brands is unpacked in Ozempic versus Wegovy, and the medication is introduced more broadly in semaglutide explained.

The Three Channels of Appetite Control

The weight loss semaglutide produces comes overwhelmingly from reduced food intake, not from burning more energy. It is not a stimulant. People do not feel revved up; they feel less interested in food. That reduced interest is not a single effect but the sum of three distinct mechanisms, which is why it feels qualitatively different from older appetite suppressants. A fuller treatment of these mechanisms sits in how GLP-1 affects appetite; what follows is the version specific to semaglutide.

Slowed gastric emptying

The first channel is the stomach. Semaglutide slows the rate at which the stomach empties its contents into the small intestine. A stomach that empties more slowly stays distended for longer after a meal, and gastric distension is one of the oldest and most direct satiety signals — stretch receptors in the stomach wall report fullness to the brainstem by way of the vagus nerve. The practical effect is that a given meal produces a longer-lasting sense of fullness, and the next meal arrives against a stomach that is not yet empty. People report feeling satisfied sooner and staying satisfied longer. As we will see, this same slowing is the source of the medication's most common side effects.

The hypothalamic appetite thermostat

The second channel is the hypothalamus, and specifically the arcuate nucleus — a small region at the base of the brain that behaves like an appetite thermostat. Two neuron populations dominate it: one that drives hunger and one that drives satiety. GLP-1 receptors sit on these circuits, and semaglutide's activation of them biases the balance toward satiety. Because part of the arcuate nucleus sits next to a leaky portion of the blood-brain barrier, circulating signals can reach it relatively directly, and long-acting agents like semaglutide are engineered to influence these central circuits as well as peripheral ones. The effect is to shift the brain's internal setting toward "enough."

The reward system and "food noise"

The third channel is the one that has generated the most scientific interest. Liselotte van Bloemendaal and colleagues, in a widely cited 2014 study in Diabetes, used functional MRI to show that GLP-1 receptor activation reduced activity in reward-related brain regions — the insula, amygdala, putamen, and orbitofrontal cortex — in response to images of food. Critically, the effect was specific to food. GLP-1 was not acting as a general dampener of pleasure or motivation; it was selectively turning down the reward system's response to food cues.

This is the neurobiological basis of what patients call food noise — the persistent, intrusive mental presence of food that many people with obesity describe. The circuitry that fires on every passing food cue, that pulls attention toward the kitchen, that makes leaving food on the plate genuinely hard, becomes less reactive. Many people report this quieting as more transformative than the weight loss itself, because it returns cognitive bandwidth that food management had occupied for years.

The combined picture — a stomach that empties slowly, a hypothalamus biased toward satiety, and a reward system less reactive to food cues — explains why semaglutide does not feel like older appetite suppressants. Food remains enjoyable. Meals are still anticipated. Hunger still arrives. What changes is the strength and persistence of the drive to eat, and the constant background preoccupation with food.

Semaglutide does not remove the pleasure of eating. It turns down the volume on a signalling system that, in many people with obesity, has been running unusually loud — which is why patients tend to describe the change as relief rather than deprivation.

What the STEP Trials Showed

The evidence for semaglutide in weight management is unusually strong, built on large randomised controlled trials with weight loss as a pre-specified endpoint. The defining study is STEP 1, led by John Wilding at the University of Liverpool and published in the New England Journal of Medicine in 2021.

STEP 1 randomised 1,961 adults with overweight or obesity, but without diabetes, in a 2:1 ratio to once-weekly semaglutide titrated to 2.4mg or to placebo, with both groups receiving lifestyle support. Over 68 weeks, the semaglutide group lost a mean of about 14.9% of body weight, against roughly 2.4% on placebo — a treatment difference of around twelve percentage points. About 86% of those on semaglutide lost at least 5% of their body weight, and a substantial share reached 10%, 15%, and even 20% loss. For a non-surgical intervention, that was without precedent.

To appreciate why this reset the field, it helps to remember the baseline. Before this generation of drugs, weight-loss medications typically delivered single-digit percentage reductions — figures that frequently disappointed and kept pharmacotherapy at the margins of obesity care. A mean loss of around 15% was not an incremental gain on that; it was a different order of magnitude, approaching at the high end what had previously required surgery.

Two caveats run through all of this evidence and deserve emphasis. First, the weight loss was achieved while taking the medication — the trials describe what semaglutide does during treatment, not after it. Second, averages hide wide individual variation: some participants lost a great deal, others relatively little, and a minority did not respond meaningfully. The trials establish what is possible at the population level, not what any one person should expect.

STEP 1 outcome (68 weeks)	Semaglutide 2.4mg	Placebo
Mean weight change	about −14.9%	about −2.4%
Lost at least 5% of body weight	about 86%	about 32%
Lost at least 10%	about 69%	about 12%

Why the Weight Comes Back If You Stop

This is, for most people, the most consequential question about semaglutide, and the honest answer is uncomfortable: for the majority, on current evidence, much of the lost weight returns after stopping. This is not a flaw peculiar to the drug. It is a feature of the biology of body weight, and it tells you what the medication is — and is not — doing.

The clearest evidence comes from the STEP 4 trial, led by Domenica Rubino and published in JAMA in 2021. All participants received semaglutide for an initial twenty weeks, then were randomised either to continue the drug or to switch to placebo for a further forty-eight weeks. The continuation group lost a further 7.9% of body weight. The placebo group regained an average of 6.9% — roughly two-thirds of what they had lost during the run-in. The STEP 1 trial extension, reported by Wilding and colleagues in 2022, found the same pattern after the trial ended and the drug was withdrawn: much of the lost weight returned over the following year, and the cardiometabolic improvements partly reversed alongside it.

To understand why, step back to the broader biology of weight regain, which long predates these medications. When the body loses weight, it mounts a coordinated defence. Priya Sumithran and colleagues, in a landmark 2011 study, measured appetite-regulating hormones in people a full year after a very-low-calorie diet and found most of them still dysregulated in the direction that favours regain. Ghrelin — the hunger hormone first characterised by Masayasu Kojima's group in 1999 and shown by David Cummings in 2001 to rise sharply before meals — remained elevated, while satiety hormones stayed suppressed. The hunger driver was still pushing; the satiety signals were still quiet.

Running alongside this hormonal shift is a metabolic one. Rudolph Leibel and colleagues showed in 1995 that after a 10% weight loss, resting energy expenditure falls by more than body-size change alone predicts — the body quietly burns less. Manfred Müller's 2018 review of this literature describes a system that resists downward shifts in weight strongly, through coordinated changes in hunger, satiety, and energy expenditure. James Anderson's 2001 meta-analysis put the consequence in numbers: across studies, people maintained only about 23% of their initial weight loss at five years. Roughly four-fifths came back.

Seen against that background, what semaglutide does becomes clear. It counters the biological defence of weight — quieting the elevated hunger, restoring satiety signalling, dampening the reward response to food — for as long as it is present. When it is withdrawn, the defence reasserts itself, because the underlying disposition was never removed; it was only opposed. This is how chronic-disease pharmacology generally behaves. Blood-pressure medication lowers blood pressure for as long as it is taken; stopping it returns blood pressure to its untreated state, and nobody calls that the drug failing. The same framing fits semaglutide. The question "how long do I stay on this" is biologically closer to the question one asks about a cholesterol or blood-pressure drug than about a course of antibiotics.

Side Effects Follow Directly From the Mechanism

Because semaglutide's side effects come from the same actions that produce its benefit, they are relatively predictable. The most common by far are gastrointestinal: nausea, vomiting, diarrhoea, constipation, and a sense of early fullness that can occasionally tip into discomfort. In STEP 1 these were the dominant adverse events, generally mild to moderate, and they led only a small minority to discontinue.

The reason is the slowed gastric emptying. A stomach that empties slowly is doing exactly what the drug is designed to make it do — that is part of how the satiety effect works — but the same slowing can produce nausea, particularly after large or fatty meals and especially early in treatment, before the system has adapted. The nausea is, in effect, the appetite mechanism overshooting, and for most people it settles substantially over weeks.

This is why titration is central to how semaglutide is prescribed. Treatment does not begin at the full 2.4mg dose; it starts low and steps up over months, giving the gut time to adapt at each level. Rushing that schedule is one of the most common reasons people experience side effects severe enough to stop. The expected sequence and duration of these effects is laid out in the GLP-1 side effects timeline. Rarer but more serious effects — pancreatitis, gallbladder disease, and a theoretical thyroid concern derived from rodent studies — are the reason semaglutide is a prescription medication evaluated by a clinician rather than taken casually.

The Honest Summary

Semaglutide works because it engages, durably, the system the body already uses to manage eating. It slows the stomach, biases the brain's appetite thermostat toward fullness, and quiets the reward response that keeps food mentally present. The STEP trials show that this produces weight loss of a magnitude no previous medication approached. And the same trials show that the effect depends on continued treatment, because the drug counters the body's defence of its prior weight rather than dismantling it. Understanding that is the difference between treating semaglutide as a quick fix and treating it as what the evidence suggests it is: ongoing management of a chronic, biologically defended condition that, for many people, no amount of effort at the dinner table was ever going to resolve alone.